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Reduction of Relapse after Unrelated 
Donor Stem Cell Transplantation by 
KiR-Based Graft Selection
Silke Heidenreich* and Nicolaus Kröger
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Besides donor T cells, natural killer (NK) cells are considered to have a major role in 
preventing relapse after allogeneic hematopoietic stem cell transplantation (HSCT). After 
T-cell-depleted haploidentical HSCT, a strong NK alloreactivity has been described. 
These effects have been attributed to killer-cell immunoglobulin-like receptors (KIR). 
Abundant reports suggest a major role of KIR not only on outcome after haploidentical 
HSCT but also in the unrelated donor setting. In this review, we give a brief overview of 
the mechanism of NK cell activation, nomenclature of KIR haplotypes, human leukocyte 
antigen (HLA) groups, and distinct models for prediction of NK cell alloreactivity. It can 
be concluded that KIR-ligand mismatch seems to provoke adverse effects in unrelated 
donor HSCT with reduced overall survival and increased risk for high-grade acute graft-
versus-host disease. The presence of activating KIR, as seen in KIR haplotype B, as well 
as the patient’s HLA C1/x haplotype might reduce relapse in myeloid malignancies.
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inTRODUCTiOn
Natural killer (NK) cells are considered to contribute important immune effects against leukemia 
[graft-versus-leukemia (GVL) effect] after allogeneic hematopoietic stem cell transplantation 
(HSCT). Alloreactive NK cells are considered rather save concerning the development of graft-ver-
sus-host disease (GVHD) (1–5), although a high number of activating killer-cell immunoglobulin-
like receptors (KIR) (6) or extensive NK cell stimulation (7) might promote GVHD, maybe due to 
remaining T-cells in the graft. Shah et al. (7) found an association between infusion of activated 
NK cells and occurrence of acute GVHD (aGVHD): Children with ultrahigh-risk sarcoma received 
T-cell-repleted grafts from matched unrelated donors (URDs) or matched sibling donors with subse-
quent infusion of IL-15 and 4-1BBL preactivated NK cells. Five of nine patients developed aGVHD. 
Those effects were attributed to NK cell-mediated T-cell activation (7). The biology of NK cells is 
complex, but activation by human leukocyte antigen (HLA) via the group of KIR is considered to 
be a relevant mechanism of activation. Within this review, we will provide a summary of concepts 
of KIR-mediated NK cell activation and an overview of GVL effects in haploidentical (haplo), but 
especially in URD HSCT.
Biology and Activation of nK Cells
Natural killer cells were named after their ability to kill infected or tumor cells without the need for 
prior antigen contact (8–10). They are defined by surface expression of CD56 and lack of CD3 (11). 
Unlike T cells, NK-cell receptors do not undergo rearrangement. In a process called licensing, NK 
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cells with inhibitory receptors for present HLA class I (HLA-I) 
molecules (indicating “self ”) are positively selected and stimu-
lated for proliferation, leading to a licensed and self-tolerant 
subset. Missing inhibitory receptors against HLA-I do not lead 
to depletion but to a second subset of unlicensed but self-tolerant 
NK cells (12). Activation of NK cells might be initiated by antigen 
contact, but it is executed only after integration of abundant 
activating and inhibitory signals (13, 14). Today, several NK-cell 
receptors are known. Besides KIR, other NK-cell receptors that 
have been shown to have the potential to positively influence 
outcome after allogeneic HSCT are natural cytotoxicity receptors 
(15–17) as well as activating NKG2D (18) and DNAM-1 (19, 20) 
that bind to MICA/B and ULBPs or CD112/CD155, respectively. 
Both can be induced by DNA damage (21) and seem to play a role 
in negative regulation of T-cell responses (22) and acute myeloid 
leukemia (AML)/myelodysplastic syndrome immune evasion 
(15, 23).
KiR and HLA
Killer-cell immunoglobulin-like receptors belong to type-I trans-
membrane proteins of the immunoglobulin-like receptor super-
family and recognize classical HLA-I molecules (14). The 15 KIR 
genes and 2 pseudogenes are located on chromosome 19q13.4. 
According to the number of extracellular immunoglobulin-like 
domains (D), the receptors are named KIR2D and KIR3D (24, 
25). On the cytoplasmic side, they have either long (L) inhibitory 
or short (S) activating domains (14). Inhibitory KIR bind to the 
highly polymorphic regions of HLA-I molecules: HLA-A, B, and 
C (26), while the ligands for activating KIR are poorly defined 
(14, 27).
To facilitate description of KIR-ligands, HLA-C phenotypes 
can be grouped into HLA-C group 1 and 2 according to their 
respective KIR-binding motif. HLA-C group 1 contains all ligands 
with serine at residue 77 and asparagine at residue 80 of the α1 
helix (HLA-Casn80), binding KIR2DL2/3 and 2DS2. Members 
of this group are HLA-C*01/*03/*07/*08/*12/*14/*16. HLA-C 
group 2 (HLA-Clys80) has asparagine at residue 77 and lysine at 
residue 80 and contains HLA-C*02/*04/*05/*06/*15/*17/*18. 
They are ligands for KIR2DL1 and KIR2DS1 (28–31).
KIR3DL1 binds HLA-Bw4, and KIR3DL2 and 2DS2 
bind HLA-A3 and A11 (14, 18, 32–38). Despite its structure, 
KIR2DL4 exhibits activating capacities and might bind soluble 
HLA-G (39–45). The KIR phenotype of an individual is his or 
her distinct set of inhibitory or activating KIR with an underly-
ing distinct genotype (27, 46, 47). All genotypes can be sum-
marized to a set of distinct haplotypes, which again result in the 
superordinated KIR haplotypes A or B (27, 46). KIR haplotype 
B is defined as the presence of KIR2DL5, 2DS1/2/3/5, or 3DS1, 
which have to be absent in KIR haplotype A (48). KIR2DS4 is 
the only activating KIR in haplotype A (46). KIR haplotype B/x 
(B/B or B/A) is found in about 30% of the Caucasian popula-
tion (49). A more detailed analysis includes the information, 
whether the individual KIR is coded in the centromeric (Cen) 
or telomeric (Tel) gene motif of the KIR locus, resulting in Cen-
A/A, Cen-B/x, and the respective Tel haplotypes (49–52). Thus, 
each individual expresses a certain KIR haplotype and a distinct 
HLA-C haplotype (C1/C1, C1/C2, or C2/C2). For prediction 
of alloreactive NK cell effects, the presence of HLA-C1, C2, 
and Bw4, as well as their respective KIR, are investigated (53). 
KIR2DL4 stimulation by HLA-G is considered to induce toler-
ance at the maternal–fetal barrier as well as IFN-gamma release 
of NK cells but not cytotoxicity (39, 43). KIR3DL2 and 2DS2 
stimulation by HLA-A3 and A11 is also not in the primary focus 
of altering NK cell alloreactivity. KIR3DL2 has been identified 
as a surface marker in cutaneous T-cell lymphoma (54–56). For 
KIR2DS2, a reduced survival after URD-HSCT is suspected due 
to higher incidence of GVHD (57).
Model Situations Predicting nK Cell 
Alloreactivity
Different definitions of a mismatch between the donor’s NK cells 
and the recipient’s HLA exist, depending on the method that was 
chosen for KIR and HLA (HLA-C1, C2, and Bw4) evaluation 
(Figure 1).
Missing-Self/KIR-Ligand Mismatch (Figure 1A)
Alloreactivity was initially thought to be only dependent on lack 
of inhibitory HLA-I molecules in the recipient that are present in 
the donor (“missing-self ” or “KIR-ligand mismatch” or “ligand-
incompability model”) (53, 58–60). For evaluation of KIR-ligand 
mismatch, donor and recipient are screened for expression of 
HLA: NK cells from a HLA C1/C1 donor will be alloreactive 
against a C2/C2 recipient. If a recipient expresses HLA-C1, C2, 
and Bw4, he will be resistant toward NK cell killing, as seen in 
one-third of the population (61). It is assumed, but not verified 
that the respective KIR, necessary for alloreactivity, is present in 
the donor.
Receptor–Ligand Mismatch (Figure 1B)
The receptor–ligand model states that donor NK cells become 
activated in the graft-versus-host direction; if they have inhibi-
tory KIR, for which the HLA ligands in the recipient are missing, 
the NK cells become “uninhibited” (4). Thus, in addition to the 
HLA status of the recipient, confirmatory KIR genotyping of the 
patient is required. Other than in the first model, KIR on donor 
cells and HLA on recipient cells are investigated, not “assumed.” 
This model can be considered as an improvement of the “missing 
ligand model.”
Missing Ligand Model (Figure 1C)
Here, only the recipients’ HLA are genotyped, and missing HLA-
C1, C2, or Bw4 for inhibitory KIR predict an alloreactivity of the 
graft; the presence of the respective KIR that would bind to the 
missing HLA is only assumed (53).
Presence of Activating KIR (Figure 1D)
Some theories emphasize that to achieve NK cell alloreactivity, 
“un-inhibiton” of NK cells by missing inhibitory HLA ligands 
might not be sufficient. Activation requires additional stimulation 
of activating KIR in the graft (62). In this model, alloreactivity can 
be predicted by measurement of activating KIR on donor cells. 
Some studies increase the predictive validity by detection of the 
respective activating ligands on donor cells.
FiGURe 1 | Model situations that provoke natural killer (nK) cell alloreactivity. Models are depicted as used in the present review, adopted and modified 
from Symons and Fuchs (53). Details concerning the activation mechanism are provided in the text. (A) Missing-self model, also described as “killer-cell 
immunoglobulin-like receptors (KIR)-ligand mismatch” or “ligand-incompability model”: Potential alloreactivity in the graft-versus-host direction is predicted by 
investigation of human leukocyte antigen (HLA) on donor and recipient. An HLA for inhibitory KIR that is present in the donor lacks in the recipient. The presence 
of the respective inhibitory KIR in the donor is assumed but not verified. (B) Receptor–ligand mismatch: NK cells become activated in the graft-versus-host 
direction, if they have an inhibitory KIR, for which the HLA ligand in the recipient is missing. Thus, the NK cells are “uninhibited.” Other than in (A), KIR on donor 
cells and HLA on recipient cells are investigated, not “assumed.” (C) Missing ligand: If the presence of the respective inhibitory KIR is not evaluated, but assumed 
in a model where at least one HLA-ligand is missing (HLA-C1/2 or Bw4). Other than in (A), only HLA on recipient cells but not on donor cells are evaluated. (D) 
The presence of activating KIR predicts alloreactivity in the presence of the respective activating ligand. KIR haplotype B/x contains more activating KIR than KIR 
haplotype A/A.
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Therefore, we determine mismatches on the donor and 
recipient side between ligand–ligand, receptor–ligand, and 
receptor–receptor or identify activating KIR in the donor (49, 53). 
HLA and KIR can be investigated by genotyping, phenotyping, 
or functional NK cell assays to predict alloreactivity. We would 
suggest to follow the well-described methods of Ruggeri et al. for 
genotyping and phenotyping (61).
All approaches were initially tested in the haploidentical set-
ting: The Perugia group suggests donor and recipient HLA typing 
to identify mismatch (2), followed by confirmatory donor KIR 
typing to verify a mismatch between donor KIR and recipient 
HLA ligand (“KIR-ligand mismatch” combined with a “receptor–
ligand” concept) (61). They found ligand incompatibility between 
donor and recipient in haploidentical HSCT to be associated with 
increased GVL effects and lower relapse in acute leukemia (2, 
4). KIR-ligand mismatch can be prevalent either in the graft-
versus-host direction when the donor’s KIR ligand is not shared 
by the recipient or in the host-versus-graft direction when the 
recipient’s KIR ligand is not present in the donor. The St. Jude 
group rather focuses on receptor–ligand mismatch in the haplo 
setting (63), while the researchers from Minnesota implemented 
their strategy for the URD setting by selecting KIR B/x donors 
for HLA-C1-positive recipients for improved alloreactivity (50, 
64, 65).
eviDenCe OF nK CeLL-MeDiATeD GvL 
eFFeCTS
Lessons Learned from the Haploidentical 
HSCT Setting
Much knowledge concerning NK cell-mediated alloreactivity 
has been collected due to the implementation of haploidenti-
cal HSCT. To reduce the risk of GVHD, T-cell depletion was 
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performed before graft infusion at the cost of graft rejection 
(66). These effects could be partially overcome by infusion of 
high numbers of stem cells (67). Ruggeri et  al. were the first 
to show NK cell-mediated alloreactivity in the T-cell-depleted 
haploidentical graft (5). Facilitated engraftment as well as 
tumor lysis by NK cells occurred by donor grafts that were 
KIR-ligand incompatible in the graft-versus-host direction 
without occurrence of GVHD. Since then, many other groups 
have investigated the beneficial effect of alloreactive NK cells 
in the haploidentical HSCT (2, 68) and have refined criteria for 
potential donor choice (61). The results are promising for AML 
(4, 68, 69), while lymphoid malignancies have been shown to 
be resistant in some (2, 69) but not all cases (63, 70) for KIR-
mediated NK cell effects. The present status of NK cell-mediated 
effects in haploidentical HSCT has been reviewed elsewhere (53, 
71, 72).
Results in the Unrelated-Donor  
HSCT Setting
After the identification of beneficial NK cell-mediated allore-
activity in haploidentical HSCT, efforts were made to adopt 
the findings for transplantations with URD (Table  1). Even 
though many patients already have the opportunity to receive 
a graft from an HLA-matched donor, donor choice by KIR 
repertoire is useful. Since HLA and KIR are inherited sepa-
rately, approximately 75% of HLA-identical sibling donors and 
almost 100% of matched URDs will show KIR disparities and 
might therefore be a potential source for alloreactive NK cells 
(73, 74).
KiR-Ligand Mismatch Seems to induce 
Adverse effects in URD HSCT
Davies et al. (75) were the first to perform a retrospective analysis 
of patients with HLA mismatched URD HSCT, comparing KIR-
ligand mismatch. In the analysis, no difference in any of the 
primary endpoints was achieved. Concerning the subgroup of 
myeloid malignancies, KIR-ligand mismatch resulted in worse 
OS at 5 years [13 versus 38%, P < 0.01, no use of antithymocyte 
globulin (ATG)], which was even more surprising. Others con-
firmed worse outcome for KIR-ligand mismatch in URD HSCT 
after conditioning with ATG (76–79) or without ATG (80), 
accompanied with higher infections in the early posttransplant 
period (78) or increased graft rejection, TRM, and GVHD (80). 
A recent study confirmed higher mortality and higher TRM with-
out difference in relapse in 3–5/8 HLA-mismatched KIR-ligand 
mismatched (in the host-versus-graft direction) unrelated cord 
blood transplantations for AML and acute lymphoid leukemia 
(ALL) compared to KIR-matched cord blood, while no difference 
was found for mismatch in the graft-versus-host direction or in 
a higher HLA-matched subgroup or the complete patient cohort 
(81). The authors did suggest to not using KIR-ligand mismatch 
as a criterion for cord blood selection. An earlier Eurocord study 
(82) detected favorable outcome for KIR-ligand mismatched 
transplantations in AML and ALL but used lower HLA-resolution 
techniques.
No difference in mortality after either KIR-ligand mismatched 
or HLA-mismatched but KIR-ligand matched donor–recipient 
pairs was detected by a comprehensive study of CIBMT, EBMT, 
and the Dutch transplant registry (83), investigating the results 
of 1,571 patients with myeloid malignancies with or without 
T-cell depletion. KIR-ligand mismatch was associated with 
significantly higher high-grade aGVHD, just as HLA mismatch 
at HLA-C and/or B. No predictive effects of KIR-ligand mis-
match on outcome after T-cell-repleted unrelated HSCT were 
detected in a retrospective multicenter study in France (84). 
Here, different models of NK cell alloreactivity were compared 
in a very heterogeneous cohort of patients. These investigations 
were partially designed as a response to the positive results in 
haploidentical HSCT and in a previous study by Giebel et  al. 
(85) with different results: KIR-ligand mismatch in patients with 
myeloid malignancies achieved significant higher OS and RFS 
as well as lower TRM and relapse compared to HLA mismatch 
with KIR ligand match or compared to matched URD HSCT 
with the use of pretransplant ATG. The differing results could 
be only partially attributed to the use or sparing of ATG (85): 
Although toxic (86) or immunosuppressive (87, 88) on NK 
cells, ATG has been shown to accelerate NK-cell and B-cell 
reconstitution in some (89) but not all investigations (90, 91). 
It has also been shown to decelerate the recovery of CD4+ and 
CD8+ T cells (89, 91) while sparing effector-memory T cells and 
T-regulatory cells (91). The results indicated that knowledge 
from haploidentical cannot be transferred to unrelated HSCT 
without further adaptations (75). Grafts for haploidentical 
HSCT were mainly highly T-cell depleted and performed with 
high stem-cell doses as well as no or low immunosuppression, 
resulting in fast NK cell but slow T-cell reconstitution with low 
T-cell numbers and eradication of antigen-presenting cells by 
alloreactive NK clones (2, 67, 92). Therefore, the immunologi-
cal environment during engraftment in haploidentical HSCT is 
much different from URD-HSCT.
Missing-Ligand Model and Presence  
of Activating KiR Are Predictive for 
Outcome
Later, Hsu et al. (60) identified not only KIR-ligand mismatch 
but also missing KIR ligands as protective against relapse 
in HLA mismatched but not in matched URD HSCT. These 
effects were seen in myeloid and lymphoid malignancies and 
supported by later investigations by other authors (93). In the 
study by Hsu et al. (60), the absence of HLA-C2 or HLA-Bw4 
KIR ligands was associated with lower relapse. Other authors 
confirmed the impact of HLA-C2: Absence of HLA-C2 in 
recipients of KIR2DL1-positive grafts resulted in higher inci-
dence of aGVHD after myeloablative (94) as well as reduced 
intensity (95) conditioning. The absence of C1 epitopes, as seen 
for C2/C2 recipients, has been claimed responsible for poorer 
outcome (57, 65, 96). In search for favorable KIR in URD HSCT, 
Sun et  al. (97) prospectively analyzed outcome of URD AML 
patients without in  vivo T-cell depletion by ATG. According 
to the presence or absence of activating or inhibitory KIR in 
donor and recipient, they calculated a new predictive algorithm 
5H
eidenreich and K
röger
K
IR
-B
ased G
raft S
election in H
S
C
T
Frontiers in Im
m
unology | w
w
w
.frontiersin.org
February 2017 | Volum
e 8 | A
rticle 41
TABLe 1 | Studies on nK cell alloreactivity for unrelated donors.
Reference N Median 
age 
(years)a
Disease 
(n)
Tx (n) Model Conditioning 
and graft 
source
immunosuppression Main results
Davies et al. 
(75)
175 17 CML, AML, 
ALL, MDS, 
others
MMUD (175) KIR-L MMb Myeloablative
• BM
TCD or CSA ± MTX Adverse KIR-L MM in myeloid malignancies: Lower OS at 1 and 5 years (P < 0.01). 
No difference between KIR-L M/MM in any endpoint for total cohort
Schaffer et al. 
(76)
104 29 Diverse MUD (62)/
MMUD (42)
KIR-L MM Myeloablative
• BM (80)
• PB (24)
MTX + CSA, ATG Adverse KIR-L MM: Reduced OS and RFS
Giebel et al. 
(85)
130 18–20.5 Diverse MUD (61)/
MMUD (49)
KIR-L MM Myeloablative
• BM (125)
• PB (5)
CSA, MTX, ATG Beneficial KIR-L MM: Higher OS and RFS (P = 0.0007; 4.5 years). No influence of 
HLA-MM in the patients without KIR-L MM
Bornhauser 
et al. (77)
118 42–44 AML, CML, 
MDS
MUD (54)/
MMUD (64)
KIR-L MM Myeloablative
• BM (54)
• PB (64)
ATG (118) Adverse KIR-L MM: Higher relapse for KIR-L MM (P = 0.02), but no difference in 
survival after KIR-L MM, MUD, and MMUD transplantation
Schaffer et al. 
(78)
190 35–39 Diverse MUD (94)/
MMUD (96)
KIR-L MM Myeloablative 
(168)
RIC (22)
• BM (118)
• PB (72)
CSA based (179) or TCD 
(11) plus ATG (all)
Adverse KIR-L MM: Higher infections, leading to increased TRM and reduced OS 
(P = 0.01), but no increase of relapse or GVHD
Venstrom et al. 
(96)
1,277 40.5–41.7 AML MUD (664)/
MMUD (613)
Missing ligand Myeloablative 
(1,069)
RIC/NMA (189)
• BM (689)
• PB (588)
Diverse, no ATG Adverse absence of C1: HLAC2/C2 recipients have higher relapse than HLAC1/x 
recipients (P = 0.05)
Receptor–
ligand KIR 
genes
Beneficial KIR2DS1 from C1/x donor associated with lower relapse compared to 
absence of KIR2DS1 (P = 0.003) and lower mortality (P = 0.04) w/o higher high-
grade aGVHD or TRM
Beneficial KIR3DS1 associated with lower mortality (P = 0.01) by lower TRM and 
aGVHD
No predictive effects in ALL patients (separate cohort)
De Santis et al. 
(80)
104 24 Diverse MMUD (104) KIR-L MM Myeloablative
• BM (65)
• PB (39)
No ATG Adverse: KIR-L MM (HVG): Increased graft rejection
BM: CSA, MTX (59), T-cell 
depletion (9)
Adverse KIR-L MM (GVH): Increased aGVHD grade 3–4
PB: No CSA (39) Adverse KIR-L MM (GVH or HVG): Increased TRM, decrease RFS
Beneficial high number of donor KIR: Lower GVHD and improved survival
Giebel et al. 
(57)
111 18.5–21 Diverse MUD (90)/
MMUD (21)
Missing ligand Myloablative
• BM (96)
• PB (15)
CSA, MTX, ATG Adverse absence of C1: C2/C patients have lower OS and DFS, due to higher 
relapse
Sun et al. (97) 65 45–46 AML MUD (39)/
MMUD (26)
Receptor–
receptor
Diverse CSA + MTX (65) Prediction of incidence of aGVHD possible: Activating KIR in the donor that lack in 
recipient and the lack of inhibitory KIR in the donor that are present in the recipient 
predict increased aGVHD
No ATG or TCD Indifferent results for KIR-L MM, missing ligand, number of activating KIR
(Continued )
Reference N Median 
age 
(years)a
Disease 
(n)
Tx (n) Model Conditioning 
and graft 
source
immunosuppression Main results
Giebel et al. 
(98)
25 27 ALL, AML, 
MDS, CML, 
NHL
MUD (23)/
MMUD (2)
KIR genes Myeloablative
• BM (20)
• PB (7)
CSA, MTX, ATG Adverse presence of KIR2DS1: Reduced OS and DFS due to increased GVHD and 
relapse
Indifferent presence of KIR2DS1
Kröger et al. 
(79)
142 33 AML, MDS, 
CMML, 
CML, ALL
MUD (103)/
MMUD (39)
KIR haplotype Myeloablative
• BM (67)
• PB (75)
ATG, CSA, MTX Adverse KIR B/x: Higher relapse than KIR A/A (P = 0.03), but only in AML/MDS/
CML/CMML, not ALL, resulting in lower OS
KIR-L MM Adverse KIR-L MM: Higher TRM, lower OS, no increase of GVHD
Adverse KIR3DS1, 2DS1, 2DS5 in UVA, only 2DS5 in MVA, all resulting in higher 
relapse
Farag et al. 
(83)
1,571 59–68 AML, MDS, 
CML
MMUD 
KIR-L MM 
GVH (137)
KIR-L MM Myeloablative
• BM
± T-cell depletion Indifferent KIR-L MM: For KIR-L MM (GVH/HVG) as well as KIR-L M but HLA MM 
at HLA B ± C versus HLA- and KIR-L M grafts: Same rates of increased aGVHD 
grade 3–4, TRM, treatment failure, and overall mortality compared to HLA- and 
KIR-L matched graftsMMUD 
KIR-L MM 
HVG (170)
MMUD 
KIR-L M 
(260)
MUD (1,004)
Hsu et al. (60) 1,770 34.5–35 AML, MDS, 
CML, ALL
MMUD 
(1,190)/
MUD (580)
Missing ligand Myeloablative
• BM or PB
T-cell replete grafts Beneficial: missing ligand in MMUD (defined as homozygosity of recipient HLA-B or 
C epitopes) resulting in lower relapse (P = 0.004), but not for MUD
KIR-L MM Absence of HLA-C2 or Bw4 associated with reduced relapse, no survival benefit
Indifferent KIR-L MM model in subgroup of 428 patients: no difference in relapse 
(but also not with applied missing-ligand model in same subgroup P = 0.07)
Miller et al. (93) 2,062 – AML, CML, 
MDS
MMUD/
MUD
Missing ligand - ± ATG or TCD Beneficial absence of one ligand in early stage AML or MDS: reduced relapse, 
independent from HLA match (C1/C2/Bw4)
Adverse absence of ≥1 ligand in CML: Increased late-onset high-grade acute 
GVHD
Willemze et al. 
(82)
218 12.8–15 AML, ALL MUD (42)/
MMUD 
(176)
KIR-L MM RIC (202)
Myeloablative (6)
• CB (single)
CSA based (174)
Other (44)±
ATG (196)
Beneficial KIR-L MM: Improved DFS, OS, and decrease relapse
Gagne et al. 
(84)
264 24.5 Diverse MUD (164)/
MMUD 
(100)
KIR-L MM
Missing ligand
Receptor–
ligand
Receptor–
receptor
Myeloablative
• BM
Unmanipulated BM Indifferent KIR-L MM
Adverse missing-ligand: Decreased survival but only in C1-deficient recipients, in 
myeloid malignancies
Adverse receptor–ligand mismatch: KIR3DL1 as well as KIR3DL1/3DS1 mismatch 
(GVH: D+ R–, absence of recipient HLA-Bw4) from a HLA-Bw4-negative donor is 
correlated with low OS in HLA-identical and high relapse in MMUD HSCT
(Continued )
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Reference N Median 
age 
(years)a
Disease 
(n)
Tx (n) Model Conditioning 
and graft 
source
immunosuppression Main results
Ludajic et al. 
(94)
124 42 Diverse MUD Missing ligand Myeloablative 
(90)
RIC (34)
• BM (54)
• PB (70)
CSA-based (124) ± ATG 
(30)
Adverse absence of HLA-C2 in recipients of KIR2DL1-positive grafts or KIR A/A 
grafts: Increased aGVHD
Beneficial absence of HLA-C2 in recipients of KIR2DS2-positive grafts: Decreased 
aGVHD
Cooley et al. 
(64)
448 33–34 AML MUD (209)/
MMUD 
(239)
KIR haplotype
KIR-L MM
Myeloablative
• BM (397)
• PB (51)
T-cell replete MMUD grafts Beneficial KIR B/x in KIR-L M HSCT: Compared to KIR A/A higher RFS in KIR-L M 
(MUD and MMUD) but not in KIR-L MM (MMUD)
Beneficial survival rates for KIR2DL2 and 2DS2 positive grafts
Cooley et al. 
(50)
1,409 19/39 ALL, AML MUD (687) 
MMUD 
(722)
KIR haplotype Myeloablative
• BM (942)
• PB (467)
T-cell replete MMUD grafts Beneficial KIR B/x: Higher RFS in AML but not ALL
Cen-B motifs improve outcome without increased aGVHD/cGVHD or TRM
Venstrom et al. 
(99)
1,087 35.3–37.5 AML, MDS, 
CML, ALL
MUD (670)/
MMUD 
(417)
KIR genes
KIR haplotype
Myloablative
• BM (1,050)
• PB (37)
CSA (751) Beneficial presence of KIR3DS1: Same rate of relapse but reduced TRM and 
aGVHD, resulting in lower mortality in AML and MDS. Beneficial effects increase 
with copy numbers of donor KIR3DS1
No CSA (120) Beneficial effect of KIR B/x (including KIR3DS1) similar but weaker
TCD (216)
Kröger et al. 
(100)
118 51 MM Unrelated 
(81)
KIR haplotype Myeloablative 
(12)
RIC (106)
• BM (13)
• PB (105)
ATG (110) Beneficial KIR B/x B in MUD: MUD but not MMUD haplotype B/x reaches lower 
1-year relapse than haplotype AA (P = 0.005), resulting in higher 5-year DFS 
(P = 0.009).Related (37)
Venstrom et al. 
(96)
1,277 40.5–41.7 AML MUD (664)/
MMUD 
(613)
Missing ligand
Receptor–
ligand
KIR genes
Myloablative 
(1,069)
• BM (689)
• PB (588)
CSA (346) Adverse absence of C1 and beneficial KIRSDS1: Reduced risk of relapse, if the 
allograft was derived from an HLA-C1/x donor
Tac (428) Beneficial presence of KIR3DS1: Not lower relapse but reduced TRM and aGVHD, 
resulting in lower mortality in AML
TCD (348)
Cooley et al. 
(65)
1,532 Adults and 
children
AML MUD (856)/
MMUD 
(676)
KIR haplotype Myeloablative T-cell replete MMUD grafts Beneficial KIR B/x, adverse absence of C1: Relapse protection improved by high 
KIR-B content in recipients HLA-C1/x but not C2/C2 (significant only in MMUD, not 
MUD). No effect of donor HLA
KIR gene 
content
Missing-ligand
Sobecks et al. 
(95)
909 56–57 AML, MDS MUD (712)/
MMUD 
(197)
Missing ligand RIC
• BM (169)
• PB (740)
Diverse ± ATG (317) Adverse KIR2DS1 educated in a C2/C2 donor: Higher GVHD and TRM without 
reduced relapse (AML)
Adverse ≥1 missing ligand or absence of HLA-C2: Higher aGVHD (AML)
Indifferent KIR centromeric gene content or donor activating KIR
Faridi et al. 
(49)
281 50 AML, ALL MSD (153)/
MUD (128)
Comparison 
of different 
models
Myeloablative
• BM (10)
• PB (271)
ATG, CSA, MTX Adverse KIR-KIR mismatch: Increased cGVHD in HLA C1/x recipients
Beneficial ≥1 missing ligand: Reduced relapse without improved OS
Indifferent results for KIR B
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for GVHD, in which an inhibitory KIR in the donor that lacks 
in the patients has a negative value vice versa a positive value. 
On the other hand, they could not find other models such as 
KIR-ligand, missing-ligand, or high numbers of activating KIR 
to be predictive for aGVHD (97). In general, among the activat-
ing receptors, the presence of KIR2DS2 has been shown to be 
associated with lower OS and DFS as well as higher incidence 
of GVHD, resulting in high TRM (98). The alloreactivity of 
KIR2DS1 educated in a C2/C2 donor results in higher GVHD 
and TRM without reduced relapse (95). KIRSDS1 has been 
claimed responsible for reduced risk of relapse, if the allograft 
was derived from an HLA-C1/x donor (96), but did not show 
any beneficial effects in other investigations (98). The presence 
of KIR3DS1 was not associated with lower relapse but reduced 
TRM and aGVHD, resulting in lower mortality in AML patients 
(96, 99). KIR3DL1 and KIR3DL1/3DS1 mismatch in the GVH 
direction (donor positive, recipient negative, absence of recipient 
HLA-Bw4) from a HLA-Bw4-negative donor is correlated with 
low OS in HLA-identical and high relapse in HLA-mismatched 
URD HSCT (84). There are several other investigations apart 
from the environment of URD HSCT, which might be even more 
conflicting and difficult to transfer. Our early investigations 
showed the low-alloreactive KIR haplotype A to be associated 
with lower relapse after HSCT for leukemia (79), while in a later 
analysis, KIR haplotype B was associated with improved PFS 
and OS in patients with multiple myeloma (100). Cooley et al. 
(50, 64, 65) systematically investigated the influence of the KIR 
haplotype B. In summary, a high number of KIR haplotype B 
defining receptors, especially of those coded in the centromeric 
regions, showed beneficial effects on survival of HLA C1/x AML 
recipients after ATG-free HSCT without increased GVHD and 
without benefit of KIR-ligand mismatch. No positive influence of 
haplotype B was seen in recent investigations for leukemia (49) 
but in HLA-matched URD-HSCT of non-Hogdkin lymphoma 
patients, where KIR B/x grafts led to significant lower relapse 
after 5 years compared to KIR A/A donors (P = 0.5) (101). The 
role of KIR genotypes in matched unrelated and sibling HSCT 
has recently also been investigated by Faridi et al. (49). Their aim 
was to compare the predictive value of KIR-ligand mismatch (61) 
versus the “missing-ligand” hypothesis (63) or the advantage of a 
specific KIR haplotype (50, 64, 65). They found KIR–KIR match 
to be associated with lower cGVHD for HLA C1/x recipients as 
well as lower RFS. One or more missing ligand in the unrelated 
recipient for donor KIR resulted in reduced relapse (21.6 versus 
63.6%, P = 0.001) and higher RFS without improved OS. None 
of the tested hypotheses had influence on OS, and no effect of 
donor KIR haplotype was detected.
FUTURe DiReCTiOnS
During the past years, improvement in understanding NK cell 
alloreactivity has been made by wisely modeled analyzes (49, 60, 
84). Despite clinical relevance (102–105), we still know too little 
about the NK cell education after HSCT (95). The interplay of 
NK cells and T-cells after HSCT is still subject of further inves-
tigation (105), and as we now know about KIR expression on 
9Heidenreich and Kröger KIR-Based Graft Selection in HSCT
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 41
ReFeRenCeS
1. Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, et  al. 
Suppression of graft-versus-host disease and amplification of graft- versus-
tumor effects by activated natural killer cells after allogeneic bone marrow 
transplantation. J Clin Invest (1998) 101(9):1835–42. doi:10.1172/JCI1268 
2. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, 
et al. Effectiveness of donor natural killer cell alloreactivity in mismatched 
hematopoietic transplants. Science (2002) 295(5562):2097–100. doi:10.1126/
science.1068440 
3. Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK 
cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells 
while retaining GVT effects. Blood (2010) 115(21):4293–301. doi:10.1182/
blood-2009-05-222190 
4. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor 
natural killer cell allorecognition of missing self in haploidentical hematopoi-
etic transplantation for acute myeloid leukemia: challenging its predictive 
value. Blood (2007) 110(1):433–40. doi:10.1182/blood-2006-07-038687 
5. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of 
natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell 
transplantation. Blood (1999) 94(1):333–9. 
6. Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, et al. 
The beneficial role of inhibitory KIR genes of HLA class I NK epitopes 
in haploidentically mismatched stem cell allografts may be masked by 
residual donor-alloreactive T cells causing GVHD. Tissue Antigens (2004) 
63(3):204–11. doi:10.1111/j.0001-2815.2004.00182.x 
7. Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap 
S, et  al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK 
cells following T-cell-depleted stem cell transplantation. Blood (2015) 
125(5):784–92. doi:10.1182/blood-2014-07-592881 
8. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic 
reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. 
II. Characterization of effector cells. Int J Cancer (1975) 16(2):230–9. 
doi:10.1002/ijc.2910160205 
9. Garcia-Penarrubia P, Koster FT, Kelley RO, McDowell TD, Bankhurst 
AD. Antibacterial activity of human natural killer cells. J Exp Med (1989) 
169(1):99–113. doi:10.1084/jem.169.1.99 
10. Biron CA, Brossay L. NK cells and NKT cells in innate defense against 
viral infections. Curr Opin Immunol (2001) 13(4):458–64. doi:10.1016/
S0952-7915(00)00241-7 
11. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer 
cells. Blood (1990) 76(12):2421–38. 
12. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al. 
Licensing of natural killer cells by host major histocompatibility complex 
class I molecules. Nature (2005) 436(7051):709–13. doi:10.1038/nature03847 
13. Leiden JM, Gottesdiener KM, Quertermous T, Coury L, Bray RA, Gottschalk 
L, et al. T-cell receptor gene rearrangement and expression in human natural 
killer cells: natural killer activity is not dependent on the rearrangement and 
expression of T-cell receptor alpha, beta, or gamma genes. Immunogenetics 
(1988) 27(4):231–8. doi:10.1007/BF00376117 
14. Lanier LL. NK cell recognition. Annu Rev Immunol (2005) 23:225–74. 
doi:10.1146/annurev.immunol.23.021704.115526 
15. Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, 
et  al. Decreased expression of DNAM-1 on NK cells from acute myeloid 
leukemia patients. Immunol Cell Biol (2012) 90(1):109–15. doi:10.1038/
icb.2011.15 
16. Sivori S, Carlomagno S, Pesce S, Moretta A, Vitale M, Marcenaro E. TLR/
NCR/KIR: which one to use and when? Front Immunol (2014) 5:105. 
doi:10.3389/fimmu.2014.00105 
17. Ghasemzadeh M, Hosseini E, Schwarer AP, Pourfathollah AA. NK cell matu-
ration to CD56(dim) subset associated with high levels of NCRs overrides the 
inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential 
after allogeneic hematopoietic stem cell transplantation. Leuk Res (2016) 
43:58–65. doi:10.1016/j.leukres.2015.12.002 
18. Farag SS, Caligiuri MA. Human natural killer cell development and biology. 
Blood Rev (2006) 20(3):123–37. doi:10.1016/j.blre.2005.10.001 
19. Kearney CJ, Ramsbottom KM, Voskoboinik I, Darcy PK, Oliaro J. Loss 
of DNAM-1 ligand expression by acute myeloid leukemia cells renders 
them resistant to NK cell killing. Oncoimmunology (2016) 5(8):e1196308. 
doi:10.1080/2162402X.2016.1196308 
20. Kruse V, Hamann C, Monecke S, Cyganek L, Elsner L, Hubscher D, et al. 
Human induced pluripotent stem cells are targets for allogeneic and 
autologous natural killer (NK) cells and killing is partly mediated by 
the activating NK receptor DNAM-1. PLoS One (2015) 10(5):e0125544. 
doi:10.1371/journal.pone.0125544 
21. Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M, et  al. 
The DNA damage response: a common pathway in the regulation of NKG2D 
and DNAM-1 ligand expression in normal, infected, and cancer cells. Front 
Immunol (2014) 4:508. doi:10.3389/fimmu.2013.00508 
22. Zingoni A, Ardolino M, Santoni A, Cerboni C. NKG2D and DNAM-1 acti-
vating receptors and their ligands in NK-T cell interactions: role in the NK 
cell-mediated negative regulation of T cell responses. Front Immunol (2012) 
3:408. doi:10.3389/fimmu.2012.00408
23. Carlsten M, Baumann BC, Simonsson M, Jadersten M, Forsblom AM, 
Hammarstedt C, et al. Reduced DNAM-1 expression on bone marrow NK 
cells associated with impaired killing of CD34+ blasts in myelodysplastic 
syndrome. Leukemia (2010) 24(9):1607–16. doi:10.1038/leu.2010.149 
24. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members 
associated with HLA-C and HLA-B recognition by human natural killer 
cells. Science (1995) 268(5209):405–8. doi:10.1126/science.7716543 
25. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, et al. 
Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related 
molecules with diversity in both the extra- and intracellular domains. 
Immunity (1995) 2(5):439–49. doi:10.1016/1074-7613(95)90025-X 
26. Borges L, Cosman D. LIRs/ILTs/MIRs, inhibitory and stimulatory 
Ig-superfamily receptors expressed in myeloid and lymphoid cells. Cytokine 
Growth Factor Rev (2000) 11(3):209–17. doi:10.1016/S1359-6101(00)00007-1 
27. Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like 
receptor (KIR) genomic region: gene-order, haplotypes and allelic polymor-
phism. Immunol Rev (2002) 190:40–52. doi:10.1034/j.1600-065X.2002.19004.x 
28. Mandelboim O, Reyburn HT, Vales-Gomez M, Pazmany L, Colonna M, 
Borsellino G, et al. Protection from lysis by natural killer cells of group 1 and 
2 specificity is mediated by residue 80 in human histocompatibility leukocyte 
antigen C alleles and also occurs with empty major histocompatibility com-
plex molecules. J Exp Med (1996) 184(3):913–22. doi:10.1084/jem.184.3.913 
29. Boyington JC, Sun PD. A structural perspective on MHC class I recogni-
tion by killer cell immunoglobulin-like receptors. Mol Immunol (2002) 
38(14):1007–21. doi:10.1016/S0161-5890(02)00030-5 
T-cells (106), we need to be precise in our technical methods. To 
overcome the problem of heterogeneity, we would suggest begin-
ning with a simple multicenter prospective trial in adult patients 
with AML in first molecular complete remission, testing the 
hypothesis that the number of activating KIR in the unmanipu-
lated graft improves overall survival without increasing GVHD. 
KIR and HLA of donor and recipient should be measured by 
high-resolution genotyping and phenotyping. Every patient 
should receive the same conditioning and first-line immune 
suppression.
COnCLUSiOn
Due to heterogeneity of the conducted studies, a general recom-
mendation cannot be made. In matched URD-HSCT, a donor 
with high numbers of activating KIR can be chosen to optimize 
patient’s chances for survival.
AUTHOR COnTRiBUTiOnS
SH and NK contributed equally to the manuscript writing.
10
Heidenreich and Kröger KIR-Based Graft Selection in HSCT
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 41
30. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, 
et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobu-
lin-like receptor ligand incompatibility against melanoma and renal cell car-
cinoma cells. Blood (2004) 104(1):170–7. doi:10.1182/blood-2003-12-4438 
31. Faridi RM, Agrawal S. Killer immunoglobulin-like receptors (KIRs) and 
HLA-C allorecognition patterns implicative of dominant activation of 
natural killer cells contribute to recurrent miscarriages. Hum Reprod (2011) 
26(2):491–7. doi:10.1093/humrep/deq341 
32. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, et  al. A 
common inhibitory receptor for major histocompatibility complex class I 
molecules on human lymphoid and myelomonocytic cells. J Exp Med (1997) 
186(11):1809–18. doi:10.1084/jem.186.11.1809 
33. Samaridis J, Colonna M. Cloning of novel immunoglobulin superfamily 
receptors expressed on human myeloid and lymphoid cells: structural evi-
dence for new stimulatory and inhibitory pathways. Eur J Immunol (1997) 
27(3):660–5. doi:10.1002/eji.1830270313 
34. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper 
MA, et al. Differential cytokine and chemokine gene expression by human 
NK cells following activation with IL-18 or IL-15 in combination with 
IL-12: implications for the innate immune response. J Immunol (1999) 
162(8):4511–20. 
35. Vivier E, Anfossi N. Inhibitory NK-cell receptors on T cells: witness of the 
past, actors of the future. Nat Rev Immunol (2004) 4(3):190–8. doi:10.1038/
nri1306 
36. Fuchs A, Colonna M. The role of NK cell recognition of nectin and nec-
tin-like proteins in tumor immunosurveillance. Semin Cancer Biol (2006) 
16(5):359–66. doi:10.1016/j.semcancer.2006.07.002 
37. Guo H, Qian X. Clinical applications of adoptive natural killer cell immu-
notherapy for cancer: current status and future prospects. Onkologie (2010) 
33(7):389–95. doi:10.1159/000315698 
38. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell (2010) 
142(6):847–56. doi:10.1016/j.cell.2010.08.031 
39. Rajagopalan S, Fu J, Long EO. Cutting edge: induction of IFN-gamma 
production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 
(CD158d) in resting NK cells. J Immunol (2001) 167(4):1877–81. doi:10.4049/
jimmunol.167.4.1877 
40. Kikuchi-Maki A, Catina TL, Campbell KS. Cutting edge: KIR2DL4 
transduces signals into human NK cells through association with the Fc 
receptor gamma protein. J Immunol (2005) 174(7):3859–63. doi:10.4049/
jimmunol.174.7.3859 
41. Cantoni C, Verdiani S, Falco M, Pessino A, Cilli M, Conte R, et al. p49, a 
putative HLA class I-specific inhibitory NK receptor belonging to the immu-
noglobulin superfamily. Eur J Immunol (1998) 28(6):1980–90. doi:10.1002/
(SICI)1521-4141(199806)28:06<1980::AID-IMMU1980>3.0.CO;2-F 
42. Allan DS, Colonna M, Lanier LL, Churakova TD, Abrams JS, Ellis SA, 
et al. Tetrameric complexes of human histocompatibility leukocyte antigen 
(HLA)-G bind to peripheral blood myelomonocytic cells. J Exp Med (1999) 
189(7):1149–56. doi:10.1084/jem.189.7.1149 
43. Ponte M, Cantoni C, Biassoni R, Tradori-Cappai A, Bentivoglio G, Vitale 
C, et  al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: 
decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and 
acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci U S A (1999) 
96(10):5674–9. doi:10.1073/pnas.96.10.5674 
44. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen 
(HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 
(1999) 189(7):1093–100. doi:10.1084/jem.189.7.1093 
45. Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, Koopman LA, et al. 
Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc 
Natl Acad Sci U S A (2002) 99(25):16180–5. doi:10.1073/pnas.212643199 
46. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, 
Corliss B, et  al. Human diversity in killer cell inhibitory receptor genes. 
Immunity (1997) 7(6):753–63. doi:10.1016/S1074-7613(00)80394-5 
47. Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D, 
et al. Allelic polymorphism synergizes with variable gene content to individ-
ualize human KIR genotype. J Immunol (2002) 168(5):2307–15. doi:10.4049/
jimmunol.168.5.2307 
48. Marsh SG, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D, et al. 
Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. 
Tissue Antigens (2003) 62(1):79–86. doi:10.1034/j.1399-0039.2003.00072.x 
49. Faridi RM, Kemp TJ, Dharmani-Khan P, Lewis V, Tripathi G, Rajalingam R, 
et al. Donor-recipient matching for KIR genotypes reduces chronic GVHD 
and missing inhibitory KIR ligands protect against relapse after myeloab-
lative, HLA matched hematopoietic cell transplantation. PLoS One (2016) 
11(6):e0158242. doi:10.1371/journal.pone.0158242 
50. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al. Donor 
selection for natural killer cell receptor genes leads to superior survival after 
unrelated transplantation for acute myelogenous leukemia. Blood (2010) 
116(14):2411–9. doi:10.1182/blood-2010-05-283051 
51. Yawata M, Yawata N, Abi-Rached L, Parham P. Variation within the human 
killer cell immunoglobulin-like receptor (KIR) gene family. Crit Rev Immunol 
(2002) 22(5–6):463–82. doi:10.1615/CritRevImmunol.v22.i5-6.70 
52. Martin AM, Kulski JK, Gaudieri S, Witt CS, Freitas EM, Trowsdale J, et al. 
Comparative genomic analysis, diversity and evolution of two KIR haplo-
types A and B. Gene (2004) 335:121–31. doi:10.1016/j.gene.2004.03.018 
53. Symons HJ, Fuchs EJ. Hematopoietic SCT from partially HLA-mismatched 
(HLA-haploidentical) related donors. Bone Marrow Transplant (2008) 
42(6):365–77. doi:10.1038/bmt.2008.215 
54. Musette P, Michel L, Jean-Louis F, Bagot M, Bensussan A. Polymorphic 
expression of CD158k/p140/KIR3DL2 in Sezary patients. Blood (2003) 
101(3):1203. doi:10.1182/blood-2002-09-2915 
55. Bagot M, Moretta A, Sivori S, Biassoni R, Cantoni C, Bottino C, et al. CD4(+) 
cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobu-
lin-like receptor. Blood (2001) 97(5):1388–91. doi:10.1182/blood.V97.5.1388 
56. Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H, et al. 
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous 
anaplastic large-cell lymphoma. Br J Dermatol (2016) 175(2):325–33. 
doi:10.1111/bjd.14626 
57. Giebel S, Locatelli F, Wojnar J, Velardi A, Mina T, Giorgiani G, et  al. 
Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associ-
ated with increased risk of relapse after human leucocyte antigen-C-matched 
unrelated donor haematopoietic stem cell transplantation. Br J Haematol 
(2005) 131(4):483–6. doi:10.1111/j.1365-2141.2005.05797.x 
58. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of 
H-2-deficient lymphoma variants suggests alternative immune defence 
strategy. Nature (1986) 319(6055):675–8. doi:10.1038/319675a0 
59. Ljunggren HG, Karre K. In search of the ‘missing self ’: MHC mole-
cules and NK cell recognition. Immunol Today (1990) 11(7):237–44. 
doi:10.1016/0167-5699(90)90097-S 
60. Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD, 
et al. KIR ligands and prediction of relapse after unrelated donor hemato-
poietic cell transplantation for hematologic malignancy. Biol Blood Marrow 
Transplant (2006) 12(8):828–36. doi:10.1016/j.bbmt.2006.04.008 
61. Ruggeri L, Mancusi A, Urbani E, Velardi A. Identifying NK alloreactive 
donors for haploidentical hematopoietic stem cell transplantation. Methods 
Mol Biol (2016) 1393:141–5. doi:10.1007/978-1-4939-3338-9_14 
62. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-
positive NK cells mediate alloresponse against the C2 HLA-KIR ligand 
group in vitro. J Immunol (2007) 179(2):854–68. doi:10.4049/jimmunol.179. 
2.854 
63. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, et al. Determinants of 
antileukemia effects of allogeneic NK cells. J Immunol (2004) 172(1):644–50. 
doi:10.4049/jimmunol.172.1.644 
64. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, et al. 
Donors with group B KIR haplotypes improve relapse-free survival after 
unrelated hematopoietic cell transplantation for acute myelogenous leuke-
mia. Blood (2009) 113(3):726–32. doi:10.1182/blood-2008-07-171926 
65. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Marsh SG, et  al. 
Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and 
HLA-C mismatch enhance the clinical benefit of unrelated transplantation 
for acute myelogenous leukemia. J Immunol (2014) 192(10):4592–600. 
doi:10.4049/jimmunol.1302517 
66. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, 
Dupont B, et  al. Transplantation for severe combined immunodeficiency 
with HLA-A,B,D,DR incompatible parental marrow cells fractionated by 
soybean agglutinin and sheep red blood cells. Blood (1983) 61(2):341–8. 
67. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, et  al. 
Successful engraftment of T-cell-depleted haploidentical “three-loci” 
incompatible transplants in leukemia patients by addition of recombinant 
11
Heidenreich and Kröger KIR-Based Graft Selection in HSCT
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 41
human granulocyte colony-stimulating factor-mobilized peripheral blood 
progenitor cells to bone marrow inoculum. Blood (1994) 84(11):3948–55. 
68. Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, 
et al. Clearance of acute myeloid leukemia by haploidentical natural killer 
cells is improved using IL-2 diphtheria toxin fusion protein. Blood (2014) 
123(25):3855–63. doi:10.1182/blood-2013-10-532531 
69. Stringaris K, Adams S, Uribe M, Eniafe R, Wu CO, Savani BN, et al. Donor 
KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of 
leukemia relapse after HLA-identical sibling stem cell transplantation 
for acute myeloid leukemia but not other hematologic malignancies. Biol 
Blood Marrow Transplant (2010) 16(9):1257–64. doi:10.1016/j.bbmt.2010. 
03.004 
70. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. 
Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched 
haploidentical HSCT for pediatric patients: evaluation of the functional role 
of activating KIR and redefinition of inhibitory KIR specificity. Blood (2009) 
113(13):3119–29. doi:10.1182/blood-2008-06-164103 
71. Moretta A, Pende D, Locatelli F, Moretta L. Activating and inhibitory killer 
immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem 
cell transplantation to cure high-risk leukaemias. Clin Exp Immunol (2009) 
157(3):325–31. doi:10.1111/j.1365-2249.2009.03983.x 
72. Rezvani K, Rouce RH. The application of natural killer cell immunotherapy 
for the treatment of cancer. Front Immunol (2015) 6:578. doi:10.3389/
fimmu.2015.00578 
73. Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, Tyan 
D, et  al. Genetic control of human NK cell repertoire. J Immunol (2002) 
169(1):239–47. doi:10.4049/jimmunol.169.1.239 
74. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, Parham P. 
Reconstitution of NK cell receptor repertoire following HLA-matched hema-
topoietic cell transplantation. Blood (2003) 101(9):3730–40. doi:10.1182/
blood-2002-08-2568 
75. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, et al. 
Evaluation of KIR ligand incompatibility in mismatched unrelated donor 
hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 
(2002) 100(10):3825–7. doi:10.1182/blood-2002-04-1197 
76. Schaffer M, Aldener-Cannava A, Remberger M, Ringden O, Olerup O. 
Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome 
of unrelated stem-cell transplantation. Tissue Antigens (2003) 62(3):243–50. 
doi:10.1034/j.1399-0039.2003.00089.x 
77. Bornhauser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger 
G. Role of KIR ligand incompatibility in hematopoietic stem cell transplan-
tation using unrelated donors. Blood (2004) 103(7):2860–1; author reply 2. 
doi:10.1182/blood-2003-11-3893 
78. Schaffer M, Malmberg KJ, Ringden O, Ljunggren HG, Remberger M. 
Increased infection-related mortality in KIR-ligand-mismatched unrelated 
allogeneic hematopoietic stem-cell transplantation. Transplantation (2004) 
78(7):1081–5. doi:10.1097/01.TP.0000137103.19717.86 
79. Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, et al. 
Low number of donor activating killer immunoglobulin-like receptors 
(KIR) genes but not KIR-ligand mismatch prevents relapse and improves 
disease-free survival in leukemia patients after in  vivo T-cell depleted 
unrelated stem cell transplantation. Transplantation (2006) 82(8):1024–30. 
doi:10.1097/01.tp.0000235859.24513.43 
80. De Santis D, Bishara A, Witt CS, Nagler A, Brautbar C, Slavin S, et al. Natural 
killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors 
both influence outcome of mismatched unrelated donor bone marrow trans-
plants. Tissue Antigens (2005) 65(6):519–28. doi:10.1111/j.1399-0039.2005. 
00396.x 
81. Rocha V, Ruggeri A, Spellman S, Wang T, Sobecks R, Locatelli F, et al. Killer 
cell immunoglobulin-like receptor-ligand matching and outcomes after 
unrelated cord blood transplantation in acute myeloid leukemia. Biol Blood 
Marrow Transplant (2016) 22(7):1284–9. doi:10.1016/j.bbmt.2016.04.007 
82. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G, et al. KIR-
ligand incompatibility in the graft-versus-host direction improves outcomes 
after umbilical cord blood transplantation for acute leukemia. Leukemia 
(2009) 23(3):492–500. doi:10.1038/leu.2008.365 
83. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, et al. 
The effect of KIR ligand incompatibility on the outcome of unrelated donor 
transplantation: a report from the center for international blood and marrow 
transplant research, the European blood and marrow transplant registry, 
and the Dutch registry. Biol Blood Marrow Transplant (2006) 12(8):876–84. 
doi:10.1016/j.bbmt.2006.05.007 
84. Gagne K, Busson M, Bignon JD, Balere-Appert ML, Loiseau P, Dormoy A, 
et al. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic 
markers for outcome in unrelated hematopoietic stem cell transplantation. 
Biol Blood Marrow Transplant (2009) 15(11):1366–75. doi:10.1016/j.
bbmt.2009.06.015 
85. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. 
Survival advantage with KIR ligand incompatibility in hematopoietic stem 
cell transplantation from unrelated donors. Blood (2003) 102(3):814–9. 
doi:10.1182/blood-2003-01-0091 
86. Penack O, Fischer L, Gentilini C, Nogai A, Muessig A, Rieger K, et al. The 
type of ATG matters – natural killer cells are influenced differentially by 
Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transpl Immunol 
(2007) 18(2):85–7. doi:10.1016/j.trim.2007.05.001 
87. Neudorf S, Jones M. The effects of antithymocyte globulin on natural killer 
cells. Exp Hematol (1988) 16(10):831–5. 
88. Stauch D, Dernier A, Sarmiento Marchese E, Kunert K, Volk HD, Pratschke 
J, et al. Targeting of natural killer cells by rabbit antithymocyte globulin and 
campath-1H: similar effects independent of specificity. PLoS One (2009) 
4(3):e4709. doi:10.1371/journal.pone.0004709 
89. Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, Podgorny P, 
et  al. Immune reconstitution after anti-thymocyte globulin-conditioned 
hematopoietic cell transplantation. Cytotherapy (2012) 14(10):1258–75. 
doi:10.3109/14653249.2012.715243 
90. Giebel S, Dziaczkowska J, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Kruzel 
T, et al. The impact of immunosuppressive therapy on an early quantitative 
NK cell reconstitution after allogeneic haematopoietic cell transplantation. 
Ann Transplant (2005) 10(2):29–33. 
91. Servais S, Menten-Dedoyart C, Beguin Y, Seidel L, Gothot A, Daulne C, et al. 
Impact of pre-transplant anti-t cell globulin (ATG) on immune recovery after 
myeloablative allogeneic peripheral blood stem cell transplantation. PLoS 
One (2015) 10(6):e0130026. doi:10.1371/journal.pone.0130026 
92. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et  al. 
Treatment of high-risk acute leukemia with T-cell-depleted stem cells from 
related donors with one fully mismatched HLA haplotype. N Engl J Med 
(1998) 339(17):1186–93. doi:10.1056/NEJM199810223391702 
93. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, et al. 
Missing KIR ligands are associated with less relapse and increased graft-ver-
sus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 
(2007) 109(11):5058–61. doi:10.1182/blood-2007-01-065383 
94. Ludajic K, Balavarca Y, Bickeboller H, Rosenmayr A, Fae I, Fischer GF, et al. 
KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 
12/12 HLA matched, hematopoietic stem cell transplantation. Bone Marrow 
Transplant (2009) 44(2):97–103. doi:10.1038/bmt.2008.432 
95. Sobecks RM, Wang T, Askar M, Gallagher MM, Haagenson M, Spellman 
S, et al. Impact of KIR and HLA genotypes on outcomes after reduced-in-
tensity conditioning hematopoietic cell transplantation. Biol Blood Marrow 
Transplant (2015) 21(9):1589–96. doi:10.1016/j.bbmt.2015.05.002 
96. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, 
et al. HLA-C-dependent prevention of leukemia relapse by donor activating 
KIR2DS1. N Engl J Med (2012) 367(9):805–16. doi:10.1056/NEJMoa1200503 
97. Sun JY, Gaidulis L, Dagis A, Palmer J, Rodriguez R, Miller MM, et al. Killer 
Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute 
GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow 
Transplant (2005) 36(6):525–30. doi:10.1038/sj.bmt.1705089 
98. Giebel S, Nowak I, Wojnar J, Markiewicz M, Dziaczkowska J, Wylezol I, 
et al. Impact of activating killer immunoglobulin-like receptor genotype on 
outcome of unrelated donor-hematopoietic cell transplantation. Transplant 
Proc (2006) 38(1):287–91. doi:10.1016/j.transproceed.2005.11.091 
99. Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B, et al. 
Donor activating KIR3DS1 is associated with decreased acute GVHD in 
unrelated allogeneic hematopoietic stem cell transplantation. Blood (2010) 
115(15):3162–5. doi:10.1182/blood-2009-08-236943 
100. Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, et  al. 
Donor KIR haplotype B improves progression-free and overall survival after 
12
Heidenreich and Kröger KIR-Based Graft Selection in HSCT
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 41
allogeneic hematopoietic stem cell transplantation for multiple myeloma. 
Leukemia (2011) 25(10):1657–61. doi:10.1038/leu.2011.138 
101. Bachanova V, Weisdorf DJ, Wang T, Marsh SG, Trachtenberg E, Haagenson 
MD, et  al. Donor KIR B genotype improves progression-free survival of 
non-Hodgkin lymphoma patients receiving unrelated donor transplan-
tation. Biol Blood Marrow Transplant (2016) 22(9):1602–7. doi:10.1016/ 
j.bbmt.2016.05.016 
102. Nowak J, Koscinska K, Mika-Witkowska R, Rogatko-Koros M, Mizia S, 
Jaskula E, et al. Donor NK cell licensing in control of malignancy in hemato-
poietic stem cell transplant recipients. Am J Hematol (2014) 89(10):E176–83. 
doi:10.1002/ajh.23802 
103. Foley B, Felices M, Cichocki F, Cooley S, Verneris MR, Miller JS. The biology 
of NK cells and their receptors affects clinical outcomes after hematopoietic 
cell transplantation (HCT). Immunol Rev (2014) 258(1):45–63. doi:10.1111/
imr.12157 
104. Nowak J, Koscinska K, Mika-Witkowska R, Rogatko-Koros M, Mizia S, 
Jaskula E, et al. Role of donor activating KIR-HLA ligand-mediated NK cell 
education status in control of malignancy in hematopoietic cell transplant 
recipients. Biol Blood Marrow Transplant (2015) 21(5):829–39. doi:10.1016/ 
j.bbmt.2015.01.018 
105. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, et al. NK cell 
education after allogeneic transplantation: dissociation between recovery of 
cytokine-producing and cytotoxic functions. Blood (2011) 118(10):2784–92. 
doi:10.1182/blood-2011-04-347070 
106. Horowitz A, Guethlein LA, Nemat-Gorgani N, Norman PJ, Cooley S, 
Miller JS, et al. Regulation of adaptive NK cells and CD8 T cells by HLA-C 
correlates with allogeneic hematopoietic cell transplantation and with cyto-
megalovirus reactivation. J Immunol (2015) 195(9):4524–36. doi:10.4049/
jimmunol.1401990 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Heidenreich and Kröger. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
